High-dose chemotherapy with autologous stem cell rescue, also known as autologous stem cell transplantation, is fairly standard for patients under age 70 with lymphoma if the first treatment fails to cure them. During autologous stem cell transplantation, the patient’s own stem cells are collected from the blood, frozen, and then given back to the patient after chemotherapy.
However, patients with HIV have some special issues. Some HIV drugs could cause side effects. Some infections could happen at a higher rate. However, studies thus far do not suggest an increased risk of death compared to patients without HIV infection.
This study is being conducted to better define the risks and benefits of high-dose chemotherapy with autologous stem cell rescue in HIV-infected patients with lymphoma. The results of this study will help guide treatment decisions for future patients with HIV.